DALLAS, Nov. 12, 2021 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, today announced it will host a virtual
Key Opinion Leader (KOL) event regarding the potential
treatment of pancreatic cancer utilizing Lantern Pharma's drug
candidate LP-184, on World Pancreatic Cancer Day, Thursday, November 18th at
12:00 pm EST.
The event will be cohosted by:
- Dr. Igor Astsaturov, an
established, NCI-funded, physician scientist and co-leader of the
Marvin & Conchetta Greenberg Pancreatic Cancer Institute at Fox
Chase Cancer Center
- Dr. Ira Sharp,
retired internal medicine specialist, as well as a pancreatic
cancer survivor and cancer patient advocate
- Dr. Kishor G. Bhatia, Chief
Scientific Officer of Lantern Pharma
The event will feature discussions on the recent advances of
LP-184, a PTGR1-activated small molecule that leverages DNA repair
deficiency to selectively eradicate pancreatic cancers, and
potential clinical uses of LP-184 in an upcoming Phase I clinical
trial.
Lantern Pharma's Virtual KOL Event details are as
follows:
- Thursday, November 18, 2021,
12:00 pm EST- 1:00 pm EST
- To register for the webinar, please sign up here:
https://zoom.us/webinar/register/4916366404903/WN_91paHQLiR9ixOTIcm82B6g
- A replay of the webinar will be available on the investor
relations section of the Company's website:
ir.lanternpharma.com
Pancreatic cancer is the fourth leading cause of cancer deaths
in the United States with a
five-year survival rate of 7.9% and a 10-year survival rate of just
1%. GLOBOCAN estimates that for pancreatic cancer there
are approximately 490,000 new cases of pancreatic cancer globally
on an annual basis, with over 62,000 of those cases occurring in
North America. Due to the late
onset of symptoms, patients are often diagnosed after the cancer
has progressed to locally advanced or metastatic stages of the
disease. LP-184 is designed to target a specific subset of
pancreatic cancer patients that are genetically defined, which has
the potential to increase beneficial therapeutic options for
patients and may ultimately improve survival for those with this
cancer.
LP-184 is in pre-clinical development for several targeted
indications in cancer, including pancreatic cancer and
glioblastoma. LP-184 preferentially damages DNA in cancer cells
that over-express certain biomarkers or that harbor mutations in
DNA repair pathways. LP-184 was recently granted Orphan Drug
Designation by the U.S. Food and Drug Administration for the
treatment of pancreatic cancer, and also for the treatment of
glioblastoma multiforme (GBM) and other malignant gliomas.
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eight disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and
Twitter @lanternpharma.
About RADR®
RADR® or
Response Algorithm for Drug Positioning &
Rescue, is Lantern's proprietary integrated A.I. platform
for large-scale biomarker and drug-tumor interaction data analytics
that leverages machine-learning. RADR® is used to
provide mechanistic insights about drug-tumor interactions, predict
the potential response of cancer types and subtypes to existing
drugs and drug candidates, and uncover patient groups that may
respond to potential therapies being developed by Lantern and its
collaborators.
Forward-looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, among other things, statements
relating to: future events or our future financial performance; the
potential advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators in the area of pancreatic cancer may not be
successful, (iii) the risk that none of our product candidates has
received FDA marketing approval, and we may not be able to
successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates, (iv) the risk
that no drug product based on our proprietary RADR A.I. platform
has received FDA marketing approval or otherwise been incorporated
into a commercial product, and (v) those other factors set forth in
the Risk Factors section in our Annual Report on Form 10-K for the
year ended December 31, 2020, filed
with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report
on Form 10-K for the year ended December 31,
2020 under the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
CONTACT:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-host-virtual-kol-event-on-the-potential-treatment-of-pancreatic-cancer-with-drug-candidate-lp-184-on-november-18th-world-pancreatic-cancer-day-301423103.html
SOURCE Lantern Pharma